Oxford Immunotec Global PLC (NASDAQ:OXFD) Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $19.90, for a total transaction of $59,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of OXFD opened at $14.49 on Thursday. The firm has a market capitalization of $341.84 million, a P/E ratio of 28.41 and a beta of 0.33. Oxford Immunotec Global PLC has a twelve month low of $11.88 and a twelve month high of $19.19. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04. The company has a 50 day moving average price of $13.42.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.07. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The company had revenue of $19.60 million during the quarter, compared to the consensus estimate of $19.32 million. During the same period last year, the firm earned ($0.25) earnings per share. Oxford Immunotec Global’s revenue was up 17.7% compared to the same quarter last year. As a group, research analysts anticipate that Oxford Immunotec Global PLC will post -0.24 earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the company. C M Bidwell & Associates Ltd. acquired a new stake in Oxford Immunotec Global during the 2nd quarter worth $93,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Oxford Immunotec Global during the 2nd quarter worth $805,000. JPMorgan Chase & Co. boosted its stake in Oxford Immunotec Global by 3.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 94,354 shares of the company’s stock worth $1,298,000 after purchasing an additional 3,157 shares during the period. GSA Capital Partners LLP acquired a new stake in Oxford Immunotec Global during the 2nd quarter worth $173,000. Finally, Aperio Group LLC acquired a new stake in Oxford Immunotec Global during the 2nd quarter worth $42,000. Institutional investors and hedge funds own 91.19% of the company’s stock.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Recommended Story: How interest rates affect municipal bond prices
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.